Oakbrook Investments LLC increased its position in shares of Colgate-Palmolive (NYSE:CL) by 0.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 395,049 shares of the company’s stock after buying an additional 600 shares during the quarter. Colgate-Palmolive comprises approximately 1.6% of Oakbrook Investments LLC’s portfolio, making the stock its 19th largest position. Oakbrook Investments LLC’s holdings in Colgate-Palmolive were worth $27,077,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of CL. Bank of New York Mellon Corp lifted its stake in Colgate-Palmolive by 1.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 20,359,199 shares of the company’s stock worth $1,363,050,000 after purchasing an additional 223,814 shares in the last quarter. Man Group plc lifted its stake in Colgate-Palmolive by 110.5% in the 3rd quarter. Man Group plc now owns 160,303 shares of the company’s stock worth $10,732,000 after purchasing an additional 84,136 shares in the last quarter. AQR Capital Management LLC lifted its stake in Colgate-Palmolive by 47.8% in the 3rd quarter. AQR Capital Management LLC now owns 1,366,184 shares of the company’s stock worth $91,466,000 after purchasing an additional 441,603 shares in the last quarter. Kentucky Retirement Systems purchased a new position in Colgate-Palmolive in the 3rd quarter worth approximately $4,732,000. Finally, Cohen & Steers Inc. lifted its stake in Colgate-Palmolive by 0.5% in the 3rd quarter. Cohen & Steers Inc. now owns 355,011 shares of the company’s stock worth $23,768,000 after purchasing an additional 1,917 shares in the last quarter. Hedge funds and other institutional investors own 75.99% of the company’s stock.
A number of research analysts have weighed in on CL shares. Wells Fargo & Co reissued a “hold” rating and issued a $57.00 target price on shares of Colgate-Palmolive in a research note on Friday, January 25th. Morgan Stanley set a $62.00 target price on shares of Colgate-Palmolive and gave the stock a “hold” rating in a research note on Tuesday, January 29th. Macquarie set a $57.00 price target on shares of Colgate-Palmolive and gave the company a “hold” rating in a research report on Tuesday, January 29th. Zacks Investment Research lowered shares of Colgate-Palmolive from a “hold” rating to a “strong sell” rating in a research report on Wednesday, January 30th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $61.00 price target on shares of Colgate-Palmolive in a research report on Friday, February 1st. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and five have given a buy rating to the stock. Colgate-Palmolive currently has a consensus rating of “Hold” and a consensus price target of $69.69.
Colgate-Palmolive (NYSE:CL) last announced its earnings results on Friday, April 26th. The company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.01. The company had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.86 billion. Colgate-Palmolive had a negative return on equity of 3,730.37% and a net margin of 15.08%. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.74 earnings per share. Analysts forecast that Colgate-Palmolive will post 2.83 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Friday, April 19th will be given a $0.43 dividend. This is a positive change from Colgate-Palmolive’s previous quarterly dividend of $0.42. The ex-dividend date is Wednesday, April 17th. This represents a $1.72 dividend on an annualized basis and a yield of 2.41%. Colgate-Palmolive’s payout ratio is presently 57.91%.
In other Colgate-Palmolive news, CEO Ian M. Cook sold 22,634 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $66.31, for a total value of $1,500,860.54. Following the sale, the chief executive officer now owns 1,162,793 shares of the company’s stock, valued at $77,104,803.83. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Justin Skala sold 92,643 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $70.78, for a total value of $6,557,271.54. Following the completion of the sale, the vice president now directly owns 163,653 shares in the company, valued at approximately $11,583,359.34. The disclosure for this sale can be found here. In the last three months, insiders sold 352,831 shares of company stock worth $24,752,192. 1.14% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This story was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/12/oakbrook-investments-llc-acquires-600-shares-of-colgate-palmolive-cl.html.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
Featured Article: How to identify percentage decliners
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.